The Cancer Cell Signaling (SIG) program seeks to stimulate and facilitate fundamental research in mechanisms of cell signaling. SIG does this through new faculty recruitment, and promoting program interactions, collaborations, and information sharing. Co-leaders of the program David L. Brautigan and Kimberly A. Kelly decide on program membership status in consultation with senior leadership, and act as advisors for faculty and mentors for fellows and students by encouraging team-based research projects, and participating in the weekly Cancer Center seminar series, student journal clubs, and programmatic research conferences. SIG is comprised of 25 members from 15 different basic science and clinical departments in the School of Medicine and School of Engineering and Applied Science, and 2 associate members. The high quality science by SIG has resulted in over 318 publications over the past 5 years, with 43% inter- programmatic and 10% intra-programmatic co-authorships. Total extramural funding for the Program exceeds $8.8M, including over $3.9 million from the National Cancer Institute (NCI) and $3.8M from other NIH institutes. Members of SIG are a valuable resource and highly collaborative, supporting activities throughout the Cancer Center, as one of the cornerstones of the UVA Cancer Center research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-28
Application #
9626887
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
28
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437

Showing the most recent 10 out of 539 publications